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Recombinant human protein C (rhPC) secreted in the milk of transgenic pigs was studied. 'Ikansgenes having 
different regulatory elements of the murine milk protein, whey acidic protein, were used with cDNA and genomic 
human protein C (hPC) DNA sequences to obtain lower and higher expressing animals. The cDNA pigs had a 
range of expression of about 0.1-0.5 g/l milk. Two different genomic hPC pig lines have expressed 0.3 and 1-2 g/l, 
respectively. The rhPC was first purified at yields greater than 60 per cent using a monoclonal antibody (mAb) 
to the activation site on the heavy chain of hPC. Subsequent immunopurification with a calcium-dependent mAb 
directed to the y-carboxyglutamic acid domain of the light chain of hPC was used to fractionate a population 
having a higher specific anticoagulant activity in vW. The higher percentages of Ca2+-dependent conformers 
isolated from the total rhPC by immunopurification correlated well with higher specific activity and lower 
expression. A rate limitation in y-carboxylation of rhPC was clearly identified for the higher expressing animals. 
Thus, transgenic animals with high expression levels of complex recombinant proteins produced a lower 
percentage of biologically active protein. 
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Introduction 
Human protein C (hPC) is a plasma serine protease 
important to the regulation of hemostatis. The potential 
therapeutic value of hPC has been well documented (Comp, 
1990; Mann and Bovill, 1990), but an adequate supply of 
hPC is limited by its low concentration in human plasma 
(4 kg/ml). The short supply of hPC from human plasma, 
coupled with the risk of the transmission of viral pathogens, 
results in hPC being a prime candidate for replacement by 
recombinant human protein C (rhPC) (Drohan et al., 
1994b). 
HPC is synthesized as an inactive precursor. A number of 
co- and post-translational modifications are made to the 
precursor (Fig. 1) (Grinnell et aL, 1990; McClure et al., 
1992): removal of a 42 amino acid prepropetide; vitamin K 
dependent y-carboxylation of nine glutamic acid residues in 
the first 29 amino acids of the light chain (gla domain); 
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glycosylation of four possible N-linked glycosylation sites; 
Phydroxylation of Asp"; formation of 12 disulfide bridges; 
and a Ly~ '~~-Arg '~ '  dipeptide is removed, resulting in a 
disulfide-linked heterodimer. Most circulating hPC there- 
fore consists of a heavy chain (M, about 41 kDa) connected 
by a single disulfide bond to a light chain (M, about 
21 ma).  Activation of hPC is catalyzed by a complex 
containing thrombin and thrombomodulin at the endothelial 
cell surface, with a dodecapeptide being clipped from the N- 
terminal end of the heavy chain of hPC. Activated hPC 
degrades factors VIIIa and Va, inhibiting clot formation 
(Esmon, 1985 and 1989). 
RHPC has been produced in several mammalian cell lines 
(Grinnell et al., 1990; Yan et al., 1990) and by transgenic 
animals (Drohan et al., 1994a; Morcol et aL, 1994; Valendar 
et al., 1992a, 1992b). Morcol et al. (1994) have shown that 
the primary advantage of production of recombinant 
proteins in the mammary gland of transgenic pigs versus 
cell culture is the significantly higher cell density of the 
mammary gland than the maximum cell density possible in 
cell culture medium. The rhPC produced in transgenic 
animals appears to have a number of different subpopula- 
tions (Drohan et al., 1994a; Velander et al., 1992a), as does 
plasma-derived hPC (Gelfi et al., 1985; Heeb et al., 1988; 
Miletich and Broze, 1990). 
In this work, four transgenic pig lines having steady but 
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different average rhPC expression levels during a lactation 
ranging from 90 to 1,OOO pg/ml milk were studied. The 
rhPC was purified by ion exchange and immunoaffinity 
chromatography to capture the majority of the total 
population. The purified rhPC was subsequently fraction- 
ated with a calcium-dependent monoclonal antibody, 
7D7B 10, that recognizes the y-carboxyglutamic acid 
domain of hPC (Orthner et al., 1989). The purpose of this 
study was to demonstrate a facile, immunoaffinity-based 
purification procedure of a recombinant protein from milk, 
and also to demonstrate that immunoaffinity chromatog- 
raphy can be a useful tool for isolating biologically active 
from inactive fractions of a complex recombinant protein 
population. This information is also useful for determining 
rate limitations in the biosynthesis of certain post-transla- 
tional modifications. 
Materials and Methods 
Generation of transgenic pigs 
Four different lines of transgenic pigs were used in this 
study. The founder transgenics were generated by the 
methods given in Velander et al., (1992a). Two females 
having a cDNA hPC construct (animals 115-6 and 81-1) 
and two females having a genomic hPC construct ( 11 0-1 
and 122-5) were included in this study. Both the cDNA- 
hPC genetic construct and the genomic construct cloning 
have been previously detailed (Droham et al., 1994a; 
Velander et al., 1992a). 
W 
AFFIMTY PURIFICATION OF rhPC 409 
Milk collection and handling 
Lactating cows were injected IM with 30-60 IU of oxytocin 
(Vedco Inc., St Jospeh, MO) to stimulate milk letdown. 
Letdown occurred 2-5 min after injection. Three to six 
different days during lactation were used for each pool. 
Immediately after collection the milk was diluted 1:l with 
200 m~ ethylenediamine tetra-acetic acid (EDTA), pH 7.0 
to solubilize the caseins and then stored frozen. The milk/ 
EDTA mixture was centrifuged for approximately 30 min at 
3,000 g at 2°C. The fat layer was skimmed from the diluted 
whey fraction, and the milk/EDTA mixture was centrifuged 
once more and filtered through Whatman #3 filter paper 
(clarified milk/EDTA). All milk concentration values 
reported were measured from clarified whey samples using 
a dilution factor of 1.9 to account for EDTA addition and 
removal of milk fat. 
rhPC detection in milk 
An enzyme-linked immunosorbent assay (ELISA) was used 
to measure the concentration of rhPC in the milk samples. 
Immulon I1 microtiter plates (Fsicher Scientific, Pittsburg) 
were coated overnight with 100 idwell of 5 pg/d of rabit 
anti-hPC (Sigma, St Louis, MO) in 0.1 M NaHCO,, 0.1 M 
NaCI, pH 9.6 at 4°C. Wells were then washed with 
25 m Tris, 50 mM NaCl, 0.05% Tween 20, pH 7.2 (Tris 
buffered saline-Tween), and blocked for 20 min with 25 m~ 
Tris, 50 m NaC1, 0.1 per cent bovine serum albumin 
(BSA), pH 7.2 (TBS-BSA) at room temperature. hPC 
standard (American Red Cross, Rockville, MD) and sam- 
ples in the dilution buffer (TBS-BSA) were added in 
tripicate (100 bl/well) and incubated at 37°C for 20 min. 
Wells were washed and blocked with TBS-BSA for 10 min 
at room temperature. The wells were washed and 1:lOOO 
goat anti-hPC (American Diagnostica, Greenwich, CT) in 
TBS-BSA was incubated at 37°C for 20 min. After washing, 
1 : 1000 rabbit anti-goat immunoglubulin (IgG) horseradish 
peroxidase (HRP) conjugate (Sigma, St Louis) was incu- 
bated at 37°C for 20 min. Bound chromophore was detected 
with 0-Phenylenediamine substrate (Abbot, Chicago) at 
490 nm using an EL308 Bio-Tek Microplate reader. 
Purification of rhPC from milk 
Clarified whey was diluted with two parts chilled deionized 
water and loaded columnwise at 1 cdmin  onto a Diethyl 
Sepharose FF (Pharmacia, Uppsala, Sweden) column. The 
column was washed with TBS (25 m Tris-HC1, 50 m~ 
NaCl, 0.02 per cent sodium azide, pH7.2) until a steady 
baseline abosrbance (A,,,,) was reached. The rhPC was 
then eluted from the DEAE column with TBS-0.25 M NaCl 
(25 mM Tris-HC1,0.25 M NaCl, 0.02 per cent sodium azide, 
pH 7.2), and directly loaded onto the 12A8-8861-mAb 
immunoaffinity column (at 1 cdmin)  connected in tandem 
to the DEAE column. The murine monoclonal antibody 
(mAb) 12A8-8861 was produced from hybridoma cells in 
bioreactors (Kang et al., 1992). The 12A8-8861-mAb was 
anchored on Emphaze (a gift from 3M Bioapplications, St 
Paul, MN) according to the procedure given in Subramanian 
er al. (1994). The 12A8-8861-mAb binds to the activation 
region of hPC. After loading, the 12A8-8861-mAb im- 
munoaffinity column was washed with TBS-0.25 M NaC1 
and bound rhPC was eluted with a pH 10 buffer (0.1 M 
Na,CO,, 0.15 M NaC1, 0.02 per cent sodium azide). The 
pH 10 fraction was immediately brought to neutral pH by 
the addition of Tris-HC1. The immunoaffinity column was 
then regenerated with 2 M NaSCN and 4 M NaCl. Bound 
whey proteins remaining on the DEAE column were eluted 
with 1 M NaCI, and the column was regenerated with 4 M 
NaC1. All chromatographic fractions were analyzed by 
ELISA for rhPC. 
7D7B10 Fractionation 
The pH 10 elution products were further fractionated using 
a 7D7BlO-mAb immunoaffinity column. The mAb 7D7B10 
binds to the light chain of hPC in the presence of EDTA and 
elutes fully y-carboxylated hPC in the presence of calcium 
(Orthner et aL, 1989). The immunosorbent was made by 
anchoring the mAb to Emphaze at a final density of 1 mg 
mAb/d swollen gel. The column was equilibrated in TBS- 
25 m~ EDTA before purification. The neutralized pH 10 
products were mixed 1:l with TBS-25 m EDTA, pH 7.2, 
and loaded on the 7D7B10 column at 1 cdmin.  The 
columns were loaded with pH 10 products having five times 
the maximum capacity of rhPC, washed with TBS, and 
bound rhPC was eluted with TBS-25 m~ CaCl,, followed 
by regeneration with 2 M NaSCN and then 1 M NaCl. The 
calcium and thiocyanate peaks were analyzed by ELISA for 
rhPC, and the percentage of the total rhPC bound eluted in 
the calcium peak was determined from the sum of calcium, 
thiocyanate and NaCl products. 
SDS PAGE and Western Blots 
Silver-stained sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS PAGE) was used to visualize the 
proteins in the chromatographic fractions. Gradient gels of 
9-18 per cent were poured in Bio Rad Protean IIxi 
16 x 20 cm cassettes. The total protein concentration of the 
crude chromatographic fractions was estimated by measur- 
ing the OD, and assuming an extinction coefficient of 
1 d m g .  The Bio Rad dye-binding assay using bovine 
casein in 0.16 M lactose as a standard was also used and 
similar results for total protein concentration were found 
relative to that obtained using the OD280nm ethod. A total of 
4 p,g of total protein was applied to the wells for all crude 
fractions. Purified fractions of rhPC were loaded at 0.5 p,g 
(non-reduced and 1 p,g (reduced). Molecular weight mark- 
ers were purchased from Bio Rad. 
For western blots, the proteins were electrophoresed in 
9-18 gradient gels as described earlier. Non-reduced 
samples were loaded at 0.25 &well; reduced samples were 
loaded at 0.5 pg/well. The proteins were transferred to 
Polyvinylidene difluoride membranes (Bio Rad). The block- 
ing buffer used was TBS/O.O5 per cent TweeIdO.5 per cent 
casein. The westerns were then developed with goat-anti- 
hPC (American Diagnostica) (1:lOOO dilution in 
TBSRweeIdcasein, incubated for 30 min at 37"C), rabbit- 
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anti-goat IgG HRP conjugate (Sigma) and the 
metal-enhanced DAB kit (Pierce, Rockford, IL). Bio Rad- 
prestained broad-range molecular weight markers were used 
in western blots. 
APTT Activity Assay 
The biological activity of the purified rhPC fractions was 
measured by the ability of the rhPC to prolong the activated 
partial thromboplastin time (APTT) of protein C immuno- 
deficient plasma (Martinoli and Stocker, 1986). Samples of 
the pH 10 and calcium peaks were diafiltered in Centricon 
10 diafiltration units. Four times the original sample volume 
of 1 0 m  imidazole, pH7.2, were added to each sample 
followed by a reconstitution with APTT assay buffer 
(50 m~ imidazole, 0.1 M NaCl, 0.1 per cent BSA, 0.01 per 
cent Tween 20, pH 7.4) to approximately 2 units rhPC/ml. 
hPC activator (Protac, American Diagnostica, Greenwich, 
CT) was reconstituted to 1 U/ml and 5 ml was added to each 
vial of PTT Automate 5 (American Bioproducts). Protein C- 
depleted plasma (PCDP; Sigma) and normal pooled 
reference plasma (NPRP, Sigma) were used in the assay. 
Briefly, 0.1 ml of PCDP, 0.1 ml of sample in assay buffer, 
and 0.1 ml of P'ITProtac were added to the assay tubes. 
The tubes were incubated at 37°C for 3 min, and then 
25 m~ calcium chloride was added, and the clot formation 
time was measured using an Elektra 750. Each sample was 
run in duplicate, with the average of clotting times for two 
or three dilutions of each sample reported. A standard curve 
(hPC Units versus time) was constructed using NPRP doped 
into PCDP to a total volume of 0.1 ml, followed by the 
addition of 0.1 ml of assay buffer and 0.1 ml P"/Protac. A 
value of 1 U/ml plasma (4 pg/ml) in NPRP was assumed. 
Relative specific activities of rhPC to that of hPC were 
calculated by regression analysis of AFTT clotting times. 
A SDS PAGE of a representative purification process of 
rhPC from pig 110-1 clarified milk/EDTA is shown in Fig. 
2. Initial total protein levels in the transgenic milk samples 
ranged from 60-80 mg/d  (as measured by ODlsOnm). The 
caseins (M, about 27-30 kDa) are the most difficult proteins 
to remove from the pH 10 product. Contamination by 
caseins is significant (up to approximately 20 per cent as 
judged by silver stain SDS PAGE) if the salt concentration 
of the feed to the immunoaffinity column is less than 0.25 M 
NaCl (data not shown). By directly loading the 0.25 M NaCl 
eluate from the DEAE column, weak ionic interactions 
between rhPC, caseins, and/or the immunoaffinity column 
are lessened, and a purer product is obtained (Fig. 2, lane 5).  
The yields of rhPC in the pH 10 fraction ranged from 65-80 
per cent of the total rhPC detected in the product fractions. 
The majority of rhPC not eluted in the pH 10 product was 
acounted for in the flow-through of the 8861-mAb column 
and the 2 M NaSCN fraction. 
A SDS PAGE and western blot of all the purified pH 10 
eluates are given in Figs 3 and 4, respectively. The purity of 
the rhPC in the pH 10 eluate is estimated to be greater than 
98 per cent, as judged by densitometric analysis of the 
silver-stained SDS PAGE of the non-reduced samples. The 
longer gradient gels used in this work significantly improve 
the resolution of the different populations of rhPC and hPC. 
The non-reduced samples in Figs 3a and 4 all show 
heterogeneity in the total rhPC population, with three to five 
Table 1 shows the average daily expression levels of rhPC 
in the milk of the transgenic pigs. The two females 
transgenic for the cDNA-hPC (animals 115-6 and 83-1) 
had average expression levels of rhPC in milk of about 
90pg/ml and 390pg/ml, respectively. The two females 
transgenic for the genomic-hPC (animals 110-1 and 122-5) 
had average expression levels of rhPC in milk of about 
280 pg/ml and about 1 mg/ml, respectively. 
Table 1. Average rhPC expression levels of transgenic pigs in 
this study* 
Pig Gene construct Lactation Average rhPC expression level 
no. (&ml milk1 
115-6 cDNA 2nd 90 
83-1 cDNA 2nd 390 
110-1 Genomic 2nd 280 
122-5 Genomic 1st 960 
Protein C values were measured by polyclonal ELISA. The 
average of at least three daily samples was used for each pool. 
Figure 2. 9-18 per cent Silver-stained SDS PAGE of purification 
process for transgenic pig 110-1. Lane 1: clarified milk/EDTA 
feed; lane 2: DEAE column flow through; lane 3: 12A8-8861 
column flow through; lane 4 1 M NaCl DEAE eluate; lane 5: pH 
10 product; lane 6: 12A8-8861 column 2 M NaSCN eluate; lane 7, 
hPC reference from plasma. 
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major subpopulations visible as distinct bands in the 
purified products of 115-6, 83-1 and 110-1 (Fig. 3a, lanes 
1, 2, and 3, respectively). This heterogeneity ranges in M, 
from about 55 kDa to about 66 kDa for the rhPC popula- 
tions and about 55 kDa to about 68 kDa for hPC. Two major 
populations are seen in the non-reduced products from the 
milk of the higher rhPC-expressing animal, 122-5. In all 
cases, the apparent M, of the majority of the rhPC 
populations is about 2-5 kDa lower than the analogous 
forms of hPC. The reduced products in Figs 3b and 4 show 
that, unlike hPC, about 40-50 per cent of the rhPC produced 
in all the pigs is of the single-chain form. Only about 5-10 
per cent of the hPC appears as single-chain form (Fig. 3b 
and 4; lanes 5 and 10, respectively). All three gross forms of 
the putative heavy chain appear in all the rhPC products; 
alpha, beta and gamma heavy chains. The light chain of the 
rhPC products also ran at a lower M, of about 25 kDa for 
rhPC relative to about 25-28 kDa for hPC. More heteroge- 
neity was seen in the light chain of hPC. 
The percentage of the total rhPC bound that eluted in the 
25 m CaCl, from the 7D7B10 column is given in Fig. 5. 
Approximately 33 per cent of the rhPC bound from the pH 
10 product from the milk of animal 115-6 eluted in the 
calcium fraction from the 7D7B10 column. About 22 per 
cent of rhPC cfrom the pH 10 product of animal 110-1, 20 
per cent from animal 83-1 and 10 per cent from animal 
Figure4. Western blot of non-reduced and reduced pH 10 
samples. Samples were electrophoresed in 9-18 per cent SDS 
PAGE, and transferred to a PVDF membrane. Lane 1: 115-6, non- 
Figure 3. 9-18 per cent Silver stained SDS PAGE of purified pH 
samples; (b) reduced samples. 
Lane 115-6; lane 2: 83-1; lane 3: lO-l; lane 4: 122-5; lane 5: 
hPC reference from plasma. 
reduced; lane 2: 83-1, non-reduced; lane 3: 110-1, non-reduced; 
lane 6: 122-5. non-reduced; lane 5: hPC reference from plasma, 
non-reduced; lane 6 115-6, reduced; Lane 7: 83-1, reduced; lane 
8: 110-1, reduced; lane 9: 122-5, reduced; lane 10: hPC reference 
from plasma, reduced. 
products: (a) 
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Figure 5. 7D7B10 fractionation of the pH 10 products. A 707810 
immunoaffinity column was overloaded with purified rhPC from 
the pH 10 fractions. The amounts of rhPC that eluted in the 
calcium peak and the 2 M NaSCN peak were quantitated by 
ELISA. The percentage of bound rhPC eluting in the calcium 
peak is reported here. 
122-5 eluted in the calcium fraction from the 7D7B10 
immunosorbent. Fig. 5 also shows the average daily rhPC 
expression level, and the percentage of calcium-dependent 
conformer population are roughly inversely proportional to 
the average daily expression level in milk. 
The relative specific biological activities for the majority 
of the total rhPC population (pH 10 fraction from the 12A8- 
8861 mAb column) and the calacium subpopulation 
(calcium fraction from the 7D7B10 mAb column) as 
measured by APTT are given in Table 2. The relative 
specific activity of rhPC is expressed as a percentage of the 
specific activity of hPC. For the pH 10 fractions, 115-6 had 
the highest relative specific activity of 35 per cent, followed 
by 110-1 at 28 per cent, 83-1 at 16 per cent and 122-5 at 
13 per cent of hPC. The relative specific activities of the 
rhPC from the pH 10, 12A8-8861-mAb column products 
were about inversely proportional to the average expression 
levels. The activities of the calcium fractions for all the pigs 
were higher than the activities from the respective pH 10 
fractions. The relative specific activities of the rhPC from 
the Ca2'-7D7B10 mAb column products ranged from 67 
per cent for rhPC from animal 11 5-6, 75 per cent for rhPC 
Table 2. Summary of APTT activities measured for pH 10 and 
dcium fractions* 
Pig APTT activity of pHlO APTT activity of Average rhPC 
no. fraction calcium fraction expression level 
(%of hPC in NPRP) (%of hPC in NPRP) (~~g/ml l  
115-6 352 1% 6723% 90 
110-1 28 2 2% 81 27% 280 
83-1 1 6 ~ 2 %  160226% 390 
122-5 1321% 75 2 3% 960 
*Activities are reported assuming values of 1 U hPC/rnl NPRP 
(250 U/mg hPC). 
from animal 122-5,81 per cent for rhPC from animal 110-1 
to 160 per cent for rhPC from animal 83-1. 
Discussion 
The first objective of this study was to purify the majority of 
the rhPC population from milk without significant yield 
losses. Porcine milk is a complex, multiphase mixture, and 
a challenging feedstock to process (Wilkins and Velander, 
1992). Ultracentrifugation and other casein-precipitating 
steps were not used, as this results in a significant loss of 
rhPC in the casein pellet (Drohan et al, 1994b and 
unpublished observations). Instetad, the casein micelles 
were solubilized with EDTA, and the milk/EDTA mixture 
was centrifuged to remove the milk fat. The rhPC was 
eluted from the ion-exchange column with a 0.25 M NaCl 
buffer. In previous studies, this salt eluate was diluted to a 
lower ionic strength and then loaded on to a 12A8-8861 
mAb column (Morcol et al., 1994). However, silver strain 
SDS PAGE of the resulting pH 10 product showed about 
10-20 per cent contamination by caseins. In an effort to 
discover what type of non-specific interactions were causing 
this contamination, the ionic strength of the 0.25 M NaCl 
eluate was left unchanged and loaded directly on to the 
12A8-8861 mAb column. Apparently, ionic interactions 
between the caseins and the rhPC and/or the immunoaffinity 
column were responsible for the casein contamination, as 
the increased ionic strength resulted in a much more pure 
pH 10 product (Figs 2-3). However, increasing the ionic 
strength of the immunoaffinity feed appeared to yield 
slower binding kinetics, as about 10-20 per cent of the rhPC 
population passed through the column. The remaining yield 
losses for the process (about 10 per cent) were from rhPC 
that remained tightly bound to the immunosorbent and 
eluted in the 2 M NaSCN-cleaning step of the column. No 
further characterization of the rhPC in the 12A8-8861 
immunoaffinity fall through or the NaSCN fractions was 
done for this study. 
The 7D7B10 mAb was developed for gentle elution 
conditions needed for large-scale purification of hPC from 
plasma (Velander et ab, 1990). Non-specific protein-protein 
interactions between rhPC, milk proteins andor the 
7D7B 10 immunosorbent resulted in prohibitively slow 
adsorption kinetics and very low yields of rhPC when 
loading a crude feed (milMEDTA and the 0 . 2 5 ~  NaCl 
DEAE eluate) on the 7D7B10 column. In contrast, the 
adsorption kinetics of rhPC on to the 12A8-8861 mAb 
immunosorbent were much faster and greater yields of rhPC 
were obtained. The rhPC was therefore first purified using 
the 12A8-8861 mAb immunosorbent, and then further 
fractionation of active from inactive populations was done 
using the 7D7B 10 mAb immunosorbent. 
A pure, biologically active fraction of the pH 10 popula- 
tion was obtained by immunofractionation with the 
calcium-dependent mAb 7D7B10 (Table 2). The 7D7B10 
binds protein C in the presence of EDTA and releases 
protein C via a conformational change of the epitope 
(residues 1-15 of NH,-terminus of the light chain) in the 
presence of calcium. Fully y-carboxylated hPC from plasma 
was shown to have a calcium-dependent interaction with 
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7D7B10 (Orthner et al., 1989). The percentage of rhPC 
eluted in a calcium dependent manner was inversely 
proportional to the average rhPC expression level during the 
respective lactations (Fig. 5) .  These data indicate that a 
higher synthesis rates (beginning at about 1 mg/d  milk), 
the biosynthetic machinery of the mammary epithelial cells 
is unable to fully y-carboxyate Glu6, Glu7, andor GluI4 in as 
much as 90 per cent of the secreted rhPC. This corresponds 
to a per cell synthesis rate of about 10-20 pgkelY24 h 
(Morcol et al., 1994). Furthermore, the calcium-dependent 
fractions of rhPC from each pig either approached 70-80 
per cent of the functional activity of hPC from a plasma 
reference pool (for rhPC from animals 115-6, 11-1, 122-3, 
or were hyperactive at about 160 per cent of reference hPC 
activity (for rhPC from animal 83-1). Thus, the calcium- 
dependent mAb immunosorbent was capable of selectively 
eluting the most active population of rhPC. 
The yields and specific activities of the rhPC from either 
the immunopurification process or the previously reported 
multistep precipitationlion-exchange process (Drohan et al., 
1994b) were similar for the same source milk. However, 
this immunoaffinity chromatographic process is more 
amenable to scale-up than the process based on multiple 
precipitation, centrifugation, filtration, and solubilization 
steps. An affinity chromatographic-based purification proc- 
ess such as presented here eliminates the need for multiple 
time-consuming, labor-intensive, low-resolution steps. 
The authors included in this study four pigs representing 
four different genetic lines of transgenic pigs, each having a 
steady expression level of rhPC throughout a normal and 
healthy lactation. The range of rhPC expression in these 
pigs covers a full order of magnitude: 100-1,OOOO kg/d 
milk. The rate limitations for post-translational modifica- 
tions can be studied here due to the wide range of 
expression levels in the porcine mammary gland coupled 
with the numerous post-translational modifications of fully 
processed hPC. The authors have previously shown that y- 
carboxylation is rate limiting in the expression of rhPC in 
transgenic mice at lower expression levels (Paleyanda et al., 
1995). 
A number of studies have investigated the contributions 
of various domains of hPC to its anticoagulant activity 
(Mesters et al., 1991, 1993a and 1993b). In this work the 
authors focused on the 'gla domain', located in the first 29 
residues of the NH,-terminal of protein C (Fig. 1). In fully 
y-carboxylated hPC, all nine glutamic acid residues in this 
region are y-carboxylated. The gla residues bind Ca2+ ions, 
enabling hPC to interact with endothelial phospholipids. An 
hPC molecule with a non-existent gla domain (Esmon et al., 
1993), or a site-specific mutated gla domain (Glu6- 
Glu7+Asp6-Asp7; Zhang and Castellino, 1990) all show 
greatly reduced activation rates and biological activities. 
The mAb 7D7B10 binds to residues 1-15 of the light chain 
NH,-terminus of hPC in the presence of EDTA, and releases 
hPC via a conformational change of the epitope in the 
presence of calcium (Orthner et al., 1989). This epitope 
contains three gla residues, including the critical gla 
residues Gla6-Gla7, identified by Zhang and Castellino 
(1990) as being essential to obtaining fully functional hPC. 
Calcium-dependent elution of protein C is not observed if 
the gla residues are not present, and harsh elution conditions 
(for example 2 M NaSCN) must then be used to remove 
bound protein C. 
Silver stain SDS PAGE and analogous western analysis 
of the purified pHlO products show that a number of 
different populations of rhPC were produced, the majority 
having a lower MI than hPC (Figs 2-4). hPC contains about 
14 per cent carbohydrate (Yan et al., 1990), and differences 
in the MI of hPC subpopulations have been shown to be 
caused by different glycosylation patterns (Miletech and 
Broze, 1990). Four N-linked sites have been identified on 
hPC, three in the heavy chain and one in the light chain. The 
reduced gel and western blot indicate that glycosylation 
patterns of the heavy chain of the rhPC samples is likely to 
be responsible for the heterogeneity seen in the non-reduced 
samples. This has been confirmed by silver stain SDS PAGE 
and analogous western analysis of deglycosylated rhPC 
(data not shown). Inspection of the gel and western blot of 
the reduced samples also reveals that the /? and y heavy 
chains for both hPC and hPC migrate with very similar M,. 
As would be predicted from the greatest permutation in 
glycoform variants due to the presence of three potential N- 
linked glycosylation sites, it is the putative a-chain of rhPC 
having that shows the greatest difference in MI to that of 
hPC. 
Heterogeneity in the rhPC light chains is visible, but is 
not as signifcant. Propeptide cleavage, differing glycosyla- 
tion and the extent of y-carboxylation can be causes of these 
differences between light chain forms. Amino terminal 
sequencing shows that propeptide is not removed in about 
20 per cent of the rhPC forms (data not shown). The 
majority of the rhPC light chains migrate with a M, of that 
of the smallest hPC light chain population, possibly due to 
different glycosylation of the light chain. 
The products from this immunopurification scheme show 
the same amount of single-chain form: about 40-50 per 
cent, as was found for differently purified rhPC reported in 
Drohan et al., (1994a). Immunofractionation using a 
different mAb to the activation peptide domain was able to 
separate some of the single-chain populations from mixed 
heterodimeric and single chain populations (Velander et al., 
1992a). A rate limitation is indicated for post-translational 
cleavage of the dipeptide L y ~ ' ~ ~ - A r g ' ~ ~  at all the expression 
levels studied here. 
In conclusion, immunoaffinity chromatography using 
mAb can be a useful method of fractionating biologically 
active populations from the gross population of a recombi- 
nant protein. A purification process including a step such as 
this may be of great importance once recombinant proteins 
gain clinical approval for use as therapeutics. In addition, 
the use of a mAb directed towards an epitope containing a 
post-translationally modified portion of the protein can help 
identify rate limitations in the synthesis and secretion 
process. The authors postulate that the rate of ycarboxyla- 
tion is a key rate-limiting step in the synthesis of 
biologically active rhPC in the porcine mammary gland. 
This hypothesis is supported by the inverse relationship 
between the rhPC expression level and the calcium- 
dependent rhPC-7D7B 10 interaction and the high 
biological activity of the calcium-dependent fraction 
obtained from the 7D7B10 column. Further study will be 
done to characterize the carbohydrate moieties, amino acid 
sequences and gla-domains of rhPC from pigs with varying 
expression levels. This study indicates that while transgenic 
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